You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Questions posed by CMS about expanding PAMA data collection expose a rift between labs and other industry stakeholders over who should report lab prices.
CareFirst BlueCross BlueShield and United Health Group join six others in FDA's Private Payor Program for providing device makers presubmission feedback.
Highmark will examine the clinical and economic impact of Biocept's Target Selector liquid biopsy in patients with non-small cell lung cancer.
The partners will conduct an exploratory study to determine how the results of Exagen's lupus test impacts primary care physician practice referral patterns.
The report states that using NIPD for trisomy 21 in high-risk women could "probably reduce" the total number of invasive tests though the data is incomplete.
Myriad Genetics said this week a top-five insurer has issued a positive medical policy decision for the Prolaris prostate cancer test. Myriad, through a spokesman, declined to identify the insurer.
Cigna is the first national private payor to provider coverage for the Decipher tests, which provide a genomic assessment of tumor aggressiveness.
The Center for Genomic Interpretation and NSGC want payors to cover confirmatory testing for patients with positive results from 23andMe's FDA-cleared test.
UnitedHealthcare announced a new lab partnership with Quest, while LabCorp said it will become a preferred national lab for Aetna.
CMS will reimburse FoundationOne CDx at a rate of $3,500 per test for a nine-month period starting July 1.